Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on February 26, 2014, regarding an event that occurred on February 21, 2014. The filing addresses a change in the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance matters and contains no financial performance data.
Material Changes
The material change reported is the confirmed resignation of Victor J. Dzau, M.D., from the Board of Directors. Dr. Dzau intends to resign effective June 30, 2014, to accept the position of President of the Institute of Medicine, effective July 1, 2014. He will continue to serve on the Board until his resignation date.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The departure is attributed to Dr. Dzau's new professional appointment and is not described as an unusual item or a result of disagreement with the Company.
Key Facts for Investor Verification
- Victor J. Dzau, M.D., is resigning from the Board of Directors effective June 30, 2014.
- The resignation is due to his appointment as President of the Institute of Medicine.
- Dr. Dzau will remain on the Board until the effective date of his resignation.
- No financial data or operational metrics are disclosed in this specific filing.